Abstract Categories

• Advanced Practice Initiatives (such as AP-Led Practice Initiatives, Educational Initiatives, and Leadership/Professional Growth)
• AP-Led Quality Improvement (such as Quality of Care)
• AP-Led Clinical Research
• Additionally, abstracts will be considered in the following categories:
  • Precision Oncology and Biomarker-Driven Therapeutics
  • Translational Research and Drug Development
  • Early-Phase Clinical Trials and Innovative Trial Design
  • Clinical Trial Methodology and Novel Endpoints
  • Emerging Immunotherapeutic Strategies

Poster Types

• Original Research or Clinical Posters: Interim or final analyses of preclinical, translational, or clinical research studies.
• Clinical Trials in Progress: Planned or ongoing clinical trials highlighting study design, treatment schema, eligibility criteria, and scientific rationale.

Encore and/or Industry Posters

• Encore Posters are defined as posters previously presented at a national or international hematology/oncology conference within 16 months of the ACRS abstract submission deadline (February 2025).
• Encore posters may be submitted and presented, if accepted, by an author on the original abstract or an industry representative with permission.
• An Encore poster and/or poster presented by an industry representative will incur a fee of $2,500 per poster, if accepted.

Poster Specifications

• Posters may not exceed 36” x 48”
• A downloadable poster template is available HERE, or presenters may use their own design

Abstract Requirements

• Abstracts must be 250 words or fewer (titles, authors, and references are not included in the word count)
• Abstracts should include a clear statement of purpose and be organized with section headings (eg, Background, Methods, Results, Conclusions)
• All authors and their institutions must be listed, with the presenting author in bold

Submission Deadline

Abstracts will be accepted from Monday, March 16, 2026, through 11:59 PM ET on Friday, June 12, 2026.

Submitting Online

All abstracts must be submitted via the online submission form located HERE

Applicants must:

• Complete all sections of the application.
• Submit a separate application for each abstract – if submitting more than 1
• Upload required documentation, including:
  • Abstract
  • CV or resume of presenting author or industry representative
  • COI disclosure forms for presenting author or industry representative
  • Supporting documentation of permission and COI disclosure form from the first author if:
    • Presenting author is not the first author of the abstract
    • Industry representative is not an author on the abstract

Review and Notification

All submissions will undergo peer review for scientific quality and relevance.

Decision notifications will be emailed to the presenting author by Wednesday, July 8, 2026.

Presenter Responsibilities

• The abstract submitter must be an oncology/hematology advanced practitioner (AP): NP, PA, PharmD, CNS, or master’s degree or higher advanced practice nurse.
• All presenting authors must register for the meeting (at minimum for the day of their presentation).
• Presenting a poster at ACRS is voluntary. Horizon CME does not provide funding for registration or travel expenses.

All questions should be directed to Rachael M. Andrie, PhD, at rachael.andrie@horizoncme.com